Barclays initiated coverage of Omada Health (OMDA) with an Overweight rating and $21 price target. Omada’s digital health solution is addressing a large market given the prevalence of prediabetes, diabetes, hypertension and musculoskeletal issues, says the analyst, who thinks the company’s GLP-1 Care Track offerings could be an accelerant to adoption. The firm thinks Omada is gaining share in this cardiometabolic market, particularly from Teladoc’s (TDOC) Livongo, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMDA:
- Omada Health initiated with an Overweight at Morgan Stanley
- Omada Health initiated with a Buy at Goldman Sachs
- JPMorgan Issues Buy Rating for Omada Health, Inc. Citing Growth Potential in Underpenetrated $135 Billion Market and Strategic Partnerships
- Omada Health: A Compelling Investment Opportunity in Digital Health with Strong Growth Potential
- Omada Health: Strong Growth Prospects and Path to Profitability with Undervalued Potential